Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014114801) ANTIBODIES TARGETING CDH19 FOR MELANOMA
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2014/114801 International Application No.: PCT/EP2014/051551
Publication Date: 31.07.2014 International Filing Date: 27.01.2014
IPC:
C07K 16/28 (2006.01) ,C07K 16/30 (2006.01) ,A61K 47/48 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, California 91320, US
Inventors:
XIAO, Shouhua; US
PAN, Zheng; US
WICKRAMASINGHE, Dineli; US
JEFFRIES, M., Shawn; US
KING, Chadwick Terence; CA
CHAN, Brian Mingtung; CA
Agent:
KOCH, Andreas; Schiweck Weinzierl Koch European Patent Attorneys Landsberger Str. 98 80339 Munich, DE
Priority Data:
61/756,97725.01.2013US
61/785,11914.03.2013US
Title (EN) ANTIBODIES TARGETING CDH19 FOR MELANOMA
(FR) ANTICORPS CIBLANT CDH19 POUR UN MÉLANOME
Abstract:
(EN) The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct.
(FR) La présente invention concerne un anticorps humain ou un fragment de liaison d'antigène de celui-ci ou une construction d'anticorps comprenant un domaine de liaison ou fragment de liaison d'antigène de celui-ci capable de se lier à CDH19 humain sur la surface d'une cellule cible. La présente invention concerne une séquence d'acide nucléique codant pour l'anticorps ou un fragment de liaison d'antigène de celui-ci contenu dans la construction d'anticorps, un vecteur comprenant la séquence d'acide nucléique et une cellule hôte transformée ou transfectée avec le vecteur. De plus, la description concerne un procédé pour la production de la construction d'anticorps de la description, une utilisation médicale ou un procédé de traitement utilisant la construction d'anticorps et un kit comprenant l'anticorps ou le fragment de liaison d'antigène de celui-ci ou la construction d'anticorps.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
US20150322151EP2948478